RecruitingPhase 1

A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects

South Korea44 participantsStarted 2026-02-26

Plain-language summary

A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 Under Fed Conditions in Healthy Adult Male Subjects

Who can participate

Age range19 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit * The Age equal to or greater than 19 in healthy adult male volunteers at the time of screening visit Exclusion Criteria: * Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration * Other exclusions applied

What they're measuring

Area under the plasma concentration-time curve during dosing interval (AUCt)

Timeframe: pre-dose (0hour) to 72hours

Maximum concentration of drug in plasma (Cmax)

Timeframe: pre-dose (0hour) to 72hours

Trial details

NCT IDNCT07444385

SponsorAddpharma Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-04-22

Contact for this trial

JaeHun Jung

+82-31-891-5683 jhjung@addpharma.co.kr

View on ClinicalTrials.gov More Benign Prostatic Hyperplasia trials